Previous 10 | Next 10 |
2024-06-10 09:45:00 ET Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver disease and obesity, and, until recently, despite the...
2024-06-09 08:45:00 ET The biotech industry features many prominent companies that command plenty of attention on the market. And since the year started, few biotechs have made more noise than Viking Therapeutics (NASDAQ: VKTX) , a mid-cap drugmaker. Viking focuses on developing...
2024-06-07 11:15:07 ET Summary Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss. Viking stock has become more volatile due to competition from other ...
2024-06-06 07:45:00 ET Viking Therapeutics (NASDAQ: VKTX) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered a staggering 208% return on capital for shareholders in 2024. The reason? Investors ha...
2024-06-05 13:00:00 ET Summary The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Albertsons, Viking Therapeutics, Brandywine Realty Trust, platinum, and more are discussed in this edition. A number of veteran Seeking Alph...
2024-06-05 09:00:17 ET Summary Structure Therapeutics Inc.'s oral GLP-1 agonist, GSBR-1290, showed a 6.2% mean weight loss over 12 weeks, significantly outperforming placebo. Adverse events were high, with 89.2% experiencing nausea and 62.2% vomiting. The financial outlook is ...
2024-06-05 08:10:19 ET More on Eli Lilly Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Eli Lilly CFO Anat Ashkenaz...
2024-06-04 15:40:11 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...
2024-06-04 13:59:40 ET Viking Therapeutics Inc (NASDAQ: VKTX) is in focus today after announcing positive Phase 2b data for its treatment for biopsy-confirmed non-alcoholic steatohepatitis (NASH). $VKTX’s drug did significantly better than placebo VK2809 of the biotech fi...
2024-06-04 09:22:09 ET More on related stocks Intel's Goldman Sach's Meeting Yields Interesting Information Intel: Capitalize On The Downtrend Computex Chronicles Part 2: AMD Leaps Into Copilot+ PCs And Outlines Infrastructure GPU Roadmap Nvidia, DraftKings, ...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-01 08:15:00 ET Few biotech companies have made more noise than Viking Therapeutics (NASDAQ: VKTX) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the industry. However, Viking's prominence and stock price soared thanks ...
2024-06-30 06:53:00 ET Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's shares are up by 610% over the last three years, Altimmu...